Monday, September 20th was the first day of the WMS 2021 Virtual Congress, and a day devoted to symposia sponsored by various companies developing therapeutic treatments for neuromuscular disorders. Most […]
It’s that time of year again, when neuromuscular disease researchers clear their calendars for the Annual International Congress of the World Muscle Society (WMS), the largest conference focused solely on […]
CureDuchenne Cares Advocacy Efforts Succeed in Adding Duchenne to the Social Security Administration Compassionate Allowance List (CAL) Social Security Disability Insurance (SSDI) benefits are a financial lifeline for millions of […]
With recent clinical updates from Pfizer, Sarepta and Audenteson their programs in muscular disorders, the timely Gene Therapy for Muscular Disorders arrives as the only meeting dedicated to overcoming the translational […]
Today, CureDuchenne Ventures is pleased to share that we made a research investment into Code BioTherapeutics and their next-generation gene therapy platform. This is a promising technology aimed at overcoming […]
Built by the community, for the community, the DuchenneXchange has offered a secure place to inform, inspire and empower those living with Duchenne since its inception in 2018. By offering […]
CureDuchenne’s webinar, COVID-19 Vaccines: What the Duchenne Community Needs to Know, was an opportunity for the Duchenne community to get reliable information on COVID-19 vaccines. A panel of experts from […]
Dear Committee Members, On behalf of individuals living with Duchenne muscular dystrophy, their families, and caregivers served by CureDuchenne, I am writing to urge the Committee to include individuals with Duchenne in its recommendations for sub-populations to receive approved or authorized COVID-19 […]
Debra Miller, Founder and CEO of CureDuchenne, and Dr. Peter Marks, Director of the Center for Biological Evaluation and Research of the FDA, were featured at a Fireside Chat at […]
